A recent meta-analysis provided supporting evidence that in patients with T2D, SGLT2 inhibitors can significantly reduce VAT, subcutaneous adipose tissue, and ectopic hepatic fat [56]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.